

Docket #: S93-019

Cell Line Producing Soluble HLA-B7 - ATCC: J27-B7 (ATCC CRL-2374), C1R- B7 (ATCC® CRL-2371™)

The general purposes of this invention are 1) to provide bulk quantities of relatively pure soluble antigens of the human major histocompatibility complex; and 2) to determine whether or not soluble forms of the normally surface-bound HLA antigens could be used for diagnostic purposes and to test if they would induce tolerization rather than the immune sensitization caused by the surface bound form of those antigens. The first model used produced the HLA-B7 antigen in soluble form.

Deposited at ATCC: J27-B7 (ATCC CRL-2374)
C1R-B7 (ATCC® CRL-2371™)

Publications

- Hum Immunol. 1994 Jul;40(3):228-34.; "Soluble form of an HLA-B7 class I antigen specifically suppresses humoral alloimmunization."; Grumet FC1, Krishnaswamy S, See-Tho K, Filvaroff E, Hiraki DD.
- Hum Immunol. 1994 Jul;40(3):235-46.; "Bioengineered soluble HLA-B7. Genesis, characterization, and occurrence of dimerization."; Hiraki DD1, See-Tho K, Filvaroff E, Krishnaswamy S, de Bello W, Taidi-Laskowski B, Grumet FC.

Innovators

- F. Carl Grumet

Licensing Contact

Michael Bellas

Licensing Associate

[Email](#)